Company Encyclopedia
View More
name
ALI HEALTH
00241.HK
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark.
318.71 B
00241.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Drug RetailIndustry
Industry Ranking3/7
Industry medianB
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE11.75%B
    • Profit Margin5.84%B
    • Gross Margin25.06%C
  • Growth ScoreB
    • Revenue YoY15.31%B
    • Net Profit YoY58.33%B
    • Total Assets YoY13.20%B
    • Net Assets YoY13.61%B
  • Cash ScoreB
    • Cash Flow Margin1710.88%B
    • OCF YoY15.31%B
  • Operating ScoreA
    • Turnover1.52A
  • Debt ScoreB
    • Gearing Ratio24.49%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alibaba Health Information Technology (ALBHF) Gets a Buy from Guotai Haitong

    Guotai Haitong analyst maintained a Buy rating on Alibaba Health Information Technology with a price target of HK$5.69. The company's shares closed at HK$5.40. The general consensus rating is Moderate Buy with an average price target of $0.74.

    Tip Ranks·
    HK
    00241
    -0.91%
    Tip Ranks·
    HK
    00241
    -0.91%

    HKEX says JP Morgan's long position in Alibaba Health Information Technology increases to 10.43%

    HKEX says JP Morgan's long position in Alibaba Health Information Technology increases to 10.43%

    marketscreener·
    HK
    00241
    -0.91%
    marketscreener·
    HK
    00241
    -0.91%

    Morning Trend | ALI HEALTH approaches support with increased volume, is a short-term rebound window coming?

    Alibaba Health (241.HK) has recently faced continuous pressure in the market, with the stock price nearing the key technical support level of 5.49 yuan after last Friday's close, ending several days of decline. From a funding perspective, the main operators are becoming cautious, with a significant reduction in trading volume; however, there was a gradual warming of short-term buying near the close, indicating that some funds are attempting to enter at low prices within the key support range. The pharmaceutical sector has shown considerable volatility overall, with expectations of policy recovery gradually fermenting, especially with frequent news regarding national medical insurance negotiations and new internet healthcare policies, providing potential speculation space for leading stocks in the sector. From a technical standpoint, Alibaba Health's MACD remains in a death cross state, and the short-term moving average system shows a clear bearish arrangement, indicating a heavy bearish atmosphere. However, after a phase of adjustment, short-term oversold signals are becoming increasingly evident. If there is a volume surge during today's trading, a pulse-like rebound cannot be ruled out, but the overall trend has not undergone substantial changes. Investors are generally focused on whether the 5.49 yuan support can hold; if it breaks down with increased volume, it may trigger a new round of downward space. The ability of the market to stabilize in the short term will require continuous tracking of policy news and the flow of funds. Right-side trading suggestions still need to pay attention to position control to prevent risks. Overall, at this stage, Alibaba Health is still in a range of bottoming and probing, and investors should avoid blindly chasing highs and cutting losses, needing to further observe the gains and losses of support levels and changes in sentiment within the pharmaceutical sector

    Technical Forecast·
    HK
    00241
    -0.91%
    Technical Forecast·
    HK
    00241
    -0.91%

    Hang Seng Marks a Quiet Finish to November

    The Hang Seng index fell 87 points to 25,859, ending a four-day winning streak due to weakness in property and financial stocks. Sentiment was cautious ahead of China's PMI data and concerns over AI-driven volatility. Losses were limited by a rise in U.S. futures. Notable laggards included Anta Sports, Li Ning, Alibaba Health, Nongfu Spring, and China Overseas Land. The index was little changed for November despite a 2.5% weekly gain.

    Trading Economics·
    HK
    02020
    -0.24%
    HK
    02331
    +0.18%
    HK
    00688
    +0.30%
    Trading Economics·
    HK
    02020
    -0.24%
    HK
    02331
    +0.18%
    HK
    00688
    +0.30%

    "Hong Kong Stocks" The Hang Seng Index futures settlement day closed up 17 points, POP MART rose, ALI HEALTH fell over 5%

    The Hong Kong Hang Seng Index futures settlement day closed up 17 points at 25,945 points. ALI HEALTH's net profit grew by 39%, but its stock price fell by 5.6%. Xiaomi rose by 2.5%, Alibaba fell by 2.7%, Tencent fell by 1.3%, and Baidu fell by 1.6%. Li Auto reported a loss of 360 million RMB in the third quarter, with its stock price rising by 1.2%. Seres rose by 9.8%, and Pony.ai rose by 6.2%

    AASTOCKS·
    HK
    00241
    -0.91%
    HK
    09992
    +1.67%
    AASTOCKS·
    HK
    00241
    -0.91%
    HK
    09992
    +1.67%
    Posts
    View More

    $XTALPI(02228.HK) Goldman Sachs launched the "China AI Healthcare Index" today, with Pharmaron as the top-weighted stock $ALI HEALTH(00241.HK)$JD HEALTH(06618.HK)$PA GOODDOCTOR(01833.HK)$YIDU TECH(021...

    • 0
    © 2025 Longbridge｜Disclaimer